Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Di(Hydroxyethyl)Ether SCHEMBL8958396 | 1.00 | TSHR (0.48) | TSHRMAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17652696 | 0.98 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17144002 | 0.98 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18886328 | 0.98 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23636435 | 0.98 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25385542 | 0.98 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2ASMN1; SMN2 | |
| Tetraethylene Glycol SCHEMBL8958550 | 0.98 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2ASMN1; SMN2 | |
| Triethylene Glycol SCHEMBL9447836 | 0.98 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22022676 | 0.98 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20399044 | 0.98 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854792-B1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-12-26 | — | — | EP | claimed |
| CN-1437604-A | Carbamate and thiocarbamate podophyllotoxin derivatives, preparation method and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-08-20 | — | — | CN | claimed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4400107-A1 | IONIZABLE LIPOSOME, PREPARATION THEREOF, AND APPLICATION THEREOF IN GENE DELIVERY | Maxirna (Zhejiang) Technology Co., Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-3883926-B1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMA (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-114341128-B | Bifunctional protein degradation targeting chimeric compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240201196-A1 | NON-COVALENT HALOTAG LIGANDS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) | 2024-06-20 | — | — | US | disclosed |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| US-20050222210-A1 | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-06 | — | — | US | disclosed |
| CN-1191257-C | Carbamate and thiocarbamate podophyllotoxin derivatives, preparation method and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-03-02 | — | — | CN | disclosed |
| EP-1341790-A2 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | disclosed |
| CN-1437604-A | Carbamate and thiocarbamate podophyllotoxin derivatives, preparation method and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-08-20 | — | — | CN | disclosed |
| WO-2002046190-A2 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| US-6268391-B1 | Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases | GLAXO WELLCOME INC. | 2001-07-31 | — | — | US | disclosed |
| US-4125570-A | Method of stabilizing the gloss retention of thermosetting resins containing hydroxyl groups | PPG INDUSTRIES, INC. (US) | 1978-11-14 | — | — | US | disclosed |
| US-4018849-A | Polyurethane polyol compositions modified with an alkylenimine | PPG INDUSTRIES, INC. (US) | 1977-04-19 | — | — | US | disclosed |
| US-3962369-A | REACTION PRODUCT OF A POLYURETHANE POLYOL AND A POLYCARBOXYLIC ACID, AMINO RESIN | PPG INDUSTRIES, INC. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222210-A1 | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers | SI, VIP, PGC | TSHR 3220/4885MAPK1 525/4885MEN1 3386/4885 |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885MAPK1 2017/4885MEN1 4055/4885 |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | TSHR 3236/4885MAPK1 4104/4885MEN1 4326/4885 |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | TSHR 719/4885MAPK1 2265/4885MEN1 3881/4885 |
| US-20240201196-A1 | NON-COVALENT HALOTAG LIGANDS | HDHD5, DIMT1, METTL14 | TSHR 648/4885MAPK1 3570/4885MEN1 2788/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885MAPK1 2017/4885MEN1 4055/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | TSHR 76/4885MAPK1 1632/4885MEN1 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.